Venofer

Quick links to important sections

Venofer

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Venofer

Property Description
Active Ingredient Iron Sucrose
Form Sterile Solution for Injection
Pharmacological Class Iron Replacement Product
Common Use Treating Iron Deficiency
Origin Synthetic, Non-Dextran Complex

Venofer's Identity: Definition and Pharmacological Class

Venofer is the trade name for the prescription-only medicine whose active ingredient is Iron Sucrose, formally designated as an Iron replacement product and clinically recognized as an effective Antianemic agent. Its general purpose is to rapidly and reliably replenish the body's deficient iron stores when oral iron therapy is ineffective or cannot be tolerated. This medicine is used when the body needs iron but cannot absorb it well through the digestive system. As a parenteral iron preparation, Venofer is administered intravenously, serving patient groups who require controlled, direct delivery into the circulation.


Composition and Form: What is Iron Sucrose?

The active ingredient, Iron Sucrose (INN), is a synthetic, non-dextran iron complex formulated as a sterile aqueous solution for injection. The chemical structure involves Iron(III)-hydroxide complexed with sucrose, which is designed to enable the controlled delivery of iron once the preparation is in the bloodstream. Iron Sucrose is a stable complex designed to facilitate the controlled transfer of iron to the body. This specialized structure ensures the iron is available to the body without relying on variable absorption rates typically seen with digestive uptake.


General Purpose: Why is Iron Sucrose Therapy Necessary?

The core function of the therapy is to effectively correct iron deficiency, a state caused by insufficient levels of the essential mineral iron. By supplying iron directly, the medicine supports the critical process of hemoglobin synthesis within the bone marrow. This increase in the oxygen-carrying protein helps the body counteract the systemic deficit, thereby contributing to the restoration of the patient's overall capacity for oxygen transport.

Regulatory References

  1. NIH/MedlinePlus: Iron Sucrose

What side effects are possible with Venofer?

Possible Side Effects and Safety Information

This section outlines the adverse reactions and safety constraints for Venofer (iron sucrose injection) as documented in official government regulatory information.

Serious and Clinically Significant Adverse Reactions

The most serious documented risk is severe hypersensitivity reactions, including anaphylactic-type reactions, which can be life-threatening and fatal. Signs may include shock, cardiovascular collapse, and clinically significant hypotension. Due to this risk, patients must be monitored for signs and symptoms of hypersensitivity during and for at least 30 minutes after administration. Other serious reactions include acute myocardial ischemia, reported in the context of hypersensitivity.

Common Adverse Reactions

Adverse reactions reported in adult patients with chronic kidney disease (CKD) at a frequency of 2% include:

  • Vascular/Systemic: Hypotension, Peripheral edema, Chest pain, Injection site reactions.
  • Gastrointestinal: Nausea, Vomiting, Diarrhea.
  • Nervous System/Pain: Headache, Dizziness, Muscle cramp, Arthralgia, Back pain, Pain in extremity.

Safety Constraints and Monitoring

Contraindications (situations where the drug must not be used) include known hypersensitivity to Venofer or its components, or evidence of iron overload (hemosiderosis).

Monitoring: Patients require periodic monitoring of iron parameters (such as serum ferritin and transferrin saturation [TSAT]) to prevent iron accumulation. Additionally, patients should be monitored for signs of hypotension after each administration.

Population-Specific Safety Notes

The regulatory information specifies that severe maternal adverse reactions in pregnant women may cause fetal bradycardia, particularly during the second and third trimester. Caution is advised when administering to older adults due to the potential for decreased organ function.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory profile for Venofer (Iron Sucrose) addresses both acute, severe administration issues and the risk of chronic overdose. Acute manifestations, often associated with a total dosage or infusing too rapidly, can include symptoms like hypotension, headache, nausea, vomiting, and dyspnea. More severe, life-threatening outcomes documented in regulatory warnings are serious hypersensitivity reactions, shock, loss of consciousness, and circulatory collapse.

Official Regulatory Actions and Risks

Feature Regulatory Documentation Statement
Chronic Overdose Risk Excessive chronic therapy can lead to excess storage of iron, resulting in iatrogenic hemosiderosis (iron overload).
Mandated Emergency Action If signs of intolerance or a severe reaction occur, the infusion must be stopped immediately. Administration is required only when personnel and therapies are immediately available for serious reactions.
Monitoring Requirement Periodic monitoring of hematologic parameters (e.g., serum ferritin, TSAT) is required to prevent iron overload. Patients must be monitored for signs of hypersensitivity for at least 30 minutes post-infusion.
Antidote No specific antidote is detailed in the primary regulatory labeling.

Urgent medical attention must be sought immediately if any severe systemic reaction, such as circulatory distress or collapse, occurs during or shortly after administration, as these outcomes are documented as potentially fatal.

Therapeutic Uses of Venofer

What Venofer Treats: Main Uses and Benefits

Venofer (Iron Sucrose) is relevant for addressing symptoms and conditions associated with iron deficiency anemia (IDA), particularly in adult patients with Chronic Kidney Disease (CKD). The drug is indicated for the treatment of IDA in patients with CKD, including those who are dialysis-dependent and those who are non-dialysis dependent.


The core therapeutic benefit of the medicine helps replenish the body's iron stores, contributing to systemic balance. This is especially relevant in clinical scenarios where symptoms are driven by low iron, such as pronounced chronic fatigue, weakness, and reduced exercise tolerance. It is commonly used as a supportive option for individuals who experience intolerance to oral iron supplements or suffer from malabsorption syndromes (e.g., IBD, post-surgery). This supportive therapy is commonly used to help manage symptoms that interfere with daily functioning.

Quick Fact: Relief for Anemia-Related Fatigue

Venofer may assist with maintaining functional stability and contributing to easing the overall symptom load associated with systemic imbalance.

Eligibility and Restrictions for Use

Who Can and Cannot Use Venofer?

The population eligibility for Venofer (Iron Sucrose) is strictly defined by regulatory labeling to ensure appropriate use.

Eligibility Scope

Category Regulatory Statement
Approved Population Adult and Pediatric patients 2 years of age and older with Iron Deficiency Anemia (IDA) in Chronic Kidney Disease (CKD).
Age Restriction Use is not established in children under 2 years of age.

Contraindications and Restrictions

Contraindications define populations who must not use Venofer:

  • Patients with Known Hypersensitivity to iron sucrose or any of its excipients.
  • Patients with Anaemia not caused by iron deficiency.
  • Patients with Evidence of Iron Overload or hereditary disturbances in iron utilization.

Conditional Use is required for:

  • Patients with Liver Dysfunction (Hepatic Impairment), where administration must follow careful risk/benefit assessment.
  • Use is not recommended in patients with an Active or Acute Systemic Infection.
  • During Pregnancy, use is contraindicated in the first trimester, and conditional use is required in the second and third trimesters with necessary monitoring.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory documentation for Venofer (iron sucrose) focuses its interaction profile primarily on the relationship with oral iron supplements.

Documented Interactions

Interacting Product Category Interaction Summary Practical Constraint
Oral Iron Preparations Reduced absorption of the oral iron product due to pharmacodynamic interference. Oral iron therapy should not be started until at least 5 days after the final Venofer injection.

Oral Iron Preparations: Venofer, as an intravenous iron therapy, may reduce the body's ability to absorb iron from the gastrointestinal tract. This pharmacodynamic interaction necessitates a timing-based condition to prevent the reduction in the efficacy of oral iron supplements, which are often used after a course of intravenous iron. To avoid this effect, the label requires a separation period before initiating oral iron treatment.

Other Potential Interactions

No specific clinically significant drug-drug interactions involving cytochrome P450 enzymes, drug transporters (P-gp, OATP, etc.), food, alcohol, or herbal products have been documented or studied in the official regulatory product information for Venofer. The labeling does not contain specific population-dependent interaction considerations, such as for individuals with hepatic or renal impairment, within the interaction section.

Mechanism of Action

Controlled Iron Delivery and Transport

The core mechanism involves the polynuclear iron(III)-hydroxide core being processed by the reticuloendothelial system (RES), which includes specialized immune cells. This system manages the controlled dissociation of the iron-sucrose complex, releasing iron at a stable rate. The released iron immediately binds to the body's natural carrier, transferrin, which allows the iron to remain in solution and bind to circulating transferrin. The intravenous administration of the complex negates reliance on intestinal iron absorption.

Substrate Supply for Hemoglobin Synthesis

The iron-transferrin complex is actively transported to its primary destination: the erythroid precursor cells in the bone marrow. These cells utilize the iron as a direct, necessary substrate to complete the final steps of the Hemoglobin synthesis pathway. The delivery of this iron substrate drives the final steps of the Hemoglobin synthesis pathway.

Resulting Oxygen Transport Capacity

This efficient, targeted iron delivery to the bone marrow results in the incorporation of iron into hemoglobin within maturing red blood cells. The resulting increase in functional hemoglobin addresses the functional lack of substrate at the cellular level. This action ultimately increases the systemic oxygen transport capacity of the blood. This is the resulting physiological consequence of the mechanistic action.

Dosage and Administration Information

How to Use Venofer

Venofer (Iron Sucrose) administration follows established protocols regarding the route, dosing, and schedule for iron repletion in patients with Chronic Kidney Disease (CKD).


Administration and Preparation

Feature Detail
Route of Administration Strictly Intravenous (IV) use only. The medication is not administered orally or via intramuscular injection.
Preparation The solution must be diluted immediately prior to infusion, typically in 0.9% Sodium Chloride injection. It must not be mixed with other medications.
Infusion Rate Administration is performed as a slow infusion or slow injection. A 100 mg dose diluted for infusion must be administered over a minimum of 15 minutes.

Official Dosing Schedules

Administration follows cumulative regimens divided over several sessions to achieve the total required iron dose, usually 1,000 mg per course.

  • Hemodialysis-Dependent Adults: A standard dose of 100 mg elemental iron is given per consecutive dialysis session.
  • Non-Dialysis-Dependent Adults: A typical course consists of 200 mg elemental iron administered on five separate occasions over a 14-day period.
  • Pediatric Patients (≥ 2 Years): Dosing is adjusted based on body weight, typically 0.5 mg/kg (not exceeding 100 mg) per dose, following a predetermined schedule for maintenance.

Procedural Context

Because of the required controlled delivery and monitoring, Venofer must be administered in a specialized setting, such as a hospital or dialysis center, under the supervision of trained healthcare professionals. Patients are observed during administration and for at least 30 minutes after the infusion is complete to ensure procedural integrity.

Recent Clinical Evidence

Research evidence / Overview of studies for Venofer


Evidence for Use in Chronic Kidney Disease (CKD)

The research base for Venofer (Iron Sucrose) primarily focuses on its evaluation for treating iron deficiency anemia (IDA) in people with Chronic Kidney Disease (CKD). The evidence base includes many Randomized Controlled Trials (RCTs) and systematic reviews that evaluated its role in managing IDA in adult and pediatric patients (age 2 and older) with CKD, covering those who receive dialysis and those who do not. Studies monitored how iron deficiency was studied and the effect on red blood cell health.

Research examined how iron status biomarkers, such as Serum Ferritin (reflecting iron stores) and Transferrin Saturation (TSAT) (reflecting available iron), changed over short-term intervals. Studies observed that in the populations studied, there were patterns of change in these indicators following administration. Studies often compared findings against those of oral iron supplements or a control group for comparison derived from past patient information.

Study Focus: Iron Biomarkers and Hemoglobin

This research focused on the measurement of key outcomes related to functional imbalance, including charting the evolution of Hemoglobin (Hb) levels. The evidence highlights that iron status markers and Hb levels were observed to evolve during the study periods, reflecting the specific conditions under which the research was conducted.


Evidence in Other Iron Deficiency Anemia Clinical Situations

Research also has been studied for Venofer in other clinical contexts where patients experience IDA, although the evidence base here is derived from smaller-scale RCTs and broader systematic reviews. These research scenarios was evaluated in specific groups, including patients with Chronic Heart Failure (CHF) who have iron deficiency, and those with certain gastrointestinal conditions like Inflammatory Bowel Disease (IBD).


Evidence Gaps and Areas for Further Research

Evidence quality varies across different conditions; the foundational evidence in CKD is extensive, but data for other conditions are still emerging. Comparative evidence is lacking in large, dedicated trials that directly assess Venofer against all other intravenous iron formulations for long-term outcomes. The focus of many trials on short-term biomarker change means that the long-term effects on daily functioning or activity level and quality of life in the general IDA population are not fully established. Overall, studies monitor group patterns, but research does not determine whether an individual will respond similarly.

Frequently Asked Questions (FAQ)

Common questions about Venofer (FAQ)


Q: Are there different brand names for the same medicine as Venofer?

A: Venofer is the specific brand name for the active ingredient, Iron Sucrose. Official regulatory sources identify the medicine by this active ingredient.

Q: What official health bodies have approved Venofer for use?

A: Venofer (Iron Sucrose) has been approved for use by major regulatory bodies around the world. These include the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA).

Q: Does Venofer contain any components that might cause issues for vegetarians?

A: Venofer's active ingredient is Iron Sucrose, which is a synthetic complex of iron and sucrose. The regulatory description of the components lists them as a sterile aqueous solution of iron(III)-hydroxide and sucrose.

Q: Can Venofer cause a metallic taste in the mouth?

A: A change in taste (dysgeusia), such as a metallic taste, is a documented adverse reaction. This is a reported side effect found in official patient information leaflets.

Q: Can Venofer cause flu-like symptoms after treatment?

A: Official patient guides state that some patients may experience 'flu-like symptoms' after treatment. These can include headache, muscle aches, fatigue, or a low-grade fever.

Q: Is it normal to feel tired right after a Venofer treatment?

A: Fatigue (feeling weak or tired) is listed as a common adverse reaction in official patient guides. In addition, feeling weak or dizzy may be a sign of hypotension (low blood pressure), which is a serious reaction that healthcare staff monitors closely.

Q: Does Venofer make you feel jittery or anxious?

A: Post-marketing reports from official sources include general nervous system effects such as light-headedness and confusion. These are reported effects related to the central nervous system.

Q: How long do the effects of Venofer last in the body?

A: The regulatory information on Venofer's time in the body focuses on the iron component's elimination. It indicates that the iron component has an elimination half-life of approximately 6 hours. Iron repletion in the body, which is monitored by blood tests, is a process that extends beyond this kinetic fact.

Q: How quickly does Venofer start to raise ferritin levels?

A: Official labeling indicates that Transferrin Saturation (TSAT) values increase rapidly after Venofer administration. This effect is reflected in the guidance to postpone certain lab tests for at least 48 hours to prevent inaccurate readings.

Q: Why do some people need repeat Venofer treatments?

A: The regulatory information describes Venofer dosing as a course of treatment designed to correct an iron deficit. Treatment may be repeated if subsequent blood tests indicate that iron deficiency has reoccurred after the initial course is completed.

Q: Is there a maximum amount of Venofer that can be given over time?

A: The standard course for adult Chronic Kidney Disease patients is defined by a specific total amount of elemental iron. While a course may be repeated if the iron deficiency returns, official documents do not define an absolute maximum dose that can be given over a lifetime.

Q: How does Venofer compare to iron dextran in terms of how it is given?

A: Venofer is officially identified as a non-dextran iron complex, which describes its chemical structure. The official documents describe its method of administration as a slow intravenous infusion or injection.

Q: Why is a small test dose sometimes given before a full Venofer infusion?

A: While regulatory labels do not mandate a test dose, documents emphasize the serious risk of hypersensitivity reactions. Patients are required to be monitored for at least 30 minutes after infusion to address this risk, which is central to patient safety.

Q: What should I do if I think I am having an allergic reaction to Venofer?

A: Official guidance on serious hypersensitivity reactions states that if any symptoms (like swelling, trouble breathing, or dizziness) occur during the infusion, the administration must be stopped immediately. In the event this occurs, healthcare staff are trained to manage the situation.

Q: Can Venofer cause skin discoloration or staining?

A: Official documentation notes that if the medicine leaks out of the vein at the injection site (known as extravasation), it may cause pain, inflammation, and brown discoloration of the skin.

Q: Is it possible for Venofer to interfere with laboratory blood tests?

A: The regulatory label advises caution because Venofer can cause an inaccurate spike in some iron markers, such as Transferrin Saturation (TSAT). The label advises against performing serum iron measurements for at least 48 hours after administration to avoid skewed results.

Q: How long after receiving Venofer can I take my other medications?

A: Official labeling notes a specific 5-day waiting period before starting oral iron preparations after a Venofer injection. For non-iron-containing oral medications, the official documents do not list an explicit waiting period.

Q: Do I need to change my diet while receiving Venofer?

A: Official regulatory documents do not document or study specific interactions with general food, alcohol, or herbal products. The only specific dietary-related constraint is the avoidance of oral iron supplements around the time of treatment.

Q: Are there any specific activities I should avoid after getting Venofer?

A: Official patient information includes a caution regarding activities that require alertness, such as driving, until a patient understands how Venofer affects them due to the possibility of side effects like dizziness or feeling weak.

Q: Is there any research on Venofer's use in pregnant individuals?

A: Official regulatory documents confirm that safety information for use during pregnancy has been collected and studied. These documents specifically detail that severe adverse reactions in the mother may cause fetal bradycardia (slowed heart rate) during the second and third trimesters.

Q: What is the shelf life of Venofer?

A: The medicine's storage requirements specify that unopened vials should be kept at Controlled Room Temperature and protected from freezing. Once Venofer is prepared for infusion, the solution is stable for up to 7 days if stored either at room temperature or refrigerated.

How should Venofer be stored and disposed of?

How to Store and Dispose of Venofer (Iron Sucrose Injection)

The storage and handling of Venofer must adhere strictly to regulatory conditions to ensure stability and proper waste management.

Storage Requirements

Unopened vials of Venofer must be stored at Controlled Room Temperature, which is 20 C to 25 C (68 F to 77 F). The product must be protected from freezing and should be kept in its original carton. The diluted solution, when prepared with 0.9% Sodium Chloride Injection, is stable for 7 days when stored at either room temperature or under refrigeration.

Handling and Disposal

Venofer contains no preservative, mandating that any unused portion of the vial or prepared solution must be discarded immediately after use. Disposal of all expired or unused product must be conducted in accordance with local requirements and established procedures for pharmaceutical waste. As with all medicines, Venofer must be stored out of the sight and reach of children.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Venofer found in:

A-Z Index: